Thyroid cancer-related bone metastases: increasingly good prospects for treatment

@article{Duntas2018ThyroidCB,
  title={Thyroid cancer-related bone metastases: increasingly good prospects for treatment},
  author={Leonidas H. Duntas},
  journal={Endocrine},
  year={2018},
  volume={61},
  pages={1-3}
}
The incidence of bone metastases (BM) from differentiated thyroid cancer (DTC) is estimated to be as much as 13%, depending on the type of cancer, being much less common in papillary thyroid cancer than in follicular cancer, of which they are a frequent complication. The latter outcome is due both to the tumor’s tendency to spread hematogenously, this being sustained by the synthesis of adhesion molecules from follicular tumor cells that enable them to anchor to the bone matrix, and to the… CONTINUE READING
BETA
1
Twitter Mention

References

Publications referenced by this paper.
SHOWING 1-10 OF 15 REFERENCES

An evolution toward precision cancer treatment

H. Jadvar, Targeted radionuclide therapy
  • Ajr. Am. J. Roentgenol. 209, 277–288 (2017). https://doi.org/10.2214/AJR.17.18264 Endocrine
  • 2018
VIEW 1 EXCERPT

a population-based study

P. Choksi, M. Papaleontiou, +5 authors mortality in thyroid cancer
  • J. Clin. Endocrinol. Metab. 102, 1254–1260
  • 2017
VIEW 1 EXCERPT

emerging concepts

M. T. Drake, J. N. Farr, Inhibitors of sclerostin
  • Curr. Opin. Rheumatol. 26, 447–452
  • 2014

Similar Papers

Loading similar papers…